Drug intelligence / Profile preview

Qinggan Tablets

Development stage: Unknown
Lead developer: Beijing Xiehe Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Qinggan Tablets (清肝片) is a Traditional Chinese Medicine (TCM) product developed and manufactured by Conchen Pharmaceutical, a subsidiary of Consun Pharmaceutical Group. Formulated as an oral tablet, it is approved in China for the treatment of acute and chronic hepatitis. The medication is designed based on traditional principles to clear liver heat and resolve dampness, common therapeutic goals in Chinese medicine for managing liver inflammation and supporting hepatoprotective functions. As a TCM formulation, it consists of a complex mixture of botanical active ingredients that work synergistically to reduce liver damage and improve clinical symptoms associated with hepatitis.

Brand names: Qinggan Tablets
Other names: 清肝片

Beyond the preview

Go deeper on Qinggan Tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinggan Tablets.

Explore the full profile